# Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

> **NCT04607408** · PHASE1 · COMPLETED · sponsor: **HIV Vaccine Trials Network** · enrollment: 38 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** CH505TF gp120
- **BIOLOGICAL:** GLA-SE adjuvant
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04607408
- **Lead sponsor:** HIV Vaccine Trials Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-10
- **Primary completion:** 2024-07-24
- **Final completion:** 2024-07-24
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04607408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04607408, "Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04607408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*